Clinical Trials
9 trialsNCT01222767 2021-10-29
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
PharmaMar
Phase 2 Completed
NCT02955069 2021-04-12
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Novartis
Phase 2 Completed
NCT00668148 2018-07-17
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Eli Lilly and Company
Phase 2 Completed
NCT02132468 2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2 Completed
NCT01374451 2016-12-20
COOPERATE-2
Novartis
Phase 2 Terminated
NCT00563680 2016-10-27
QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
NantCell, Inc.
Phase 2 Completed
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT01658436 2016-05-02
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Novartis
Phase 2 Completed
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated